Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;12(10):11602-11610.
doi: 10.1002/cam4.5826. Epub 2023 Mar 23.

Anti-tumor effects of miR-34a by regulating immune cells in the tumor microenvironment

Man Yin  1 , Zhiqiang Zhang  1 , Yunfei Wang  2
Affiliations
Review

Anti-tumor effects of miR-34a by regulating immune cells in the tumor microenvironment

Man Yin et al. Cancer Med. 2023 May.

Abstract

Malignant tumors pose a serious threat to human health. The development of malignant tumors is characterized by uncontrolled cell division and immune evasion. The micro-ribonucleic acid-34a (miR-34a) is a small noncoding single-stranded ribonucleic acid that is ubiquitously present in normal human tissues. However, it has been confirmed to be dysregulated in a variety of tumor cells. Numerous research have revealed the importance of miR-34a in the treatment of various malignancies. MiR-34a deletion can hasten the growth of tumors whereas miR-34a overexpression suppresses the proliferation, invasion, and migration of cancer cells. Moreover, more recent studies have highlighted its role in immunity and investigated its applicability to particular tumors. Through various immune cells, factors, and other mechanisms, miR-34a can inhibit tumor carcinogenesis. In view of the important role of miR-34a in tumors, this research reviewed the aspects of miR-34a regulation of tumor immune microenvironment to exert anti-tumor effects in order to clarify the potential immunotherapy value of miR-34a in tumors.

Keywords: antitumor; immunotherapy; miR-34a; tumor immune microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non‐financial interests to disclose.

Figures

FIGURE 1
FIGURE 1
Composition of tumor microenvironment.
FIGURE 2
FIGURE 2
Targeted pathways of miR‐34a in the immune microenvironment of many cancers.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol. 2009;10(2):126‐139. doi:10.1038/nrm2632 - DOI - PubMed
    1. Garofalo M, Croce CM. MicroRNAs: master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol. 2011;51(1):25‐43. doi:10.1146/annurev-pharmtox-010510-100517 - DOI - PubMed
    1. Mendell Joshua T, Olson EN. MicroRNAs in stress signaling and human disease. Cell. 2012;148(6):1172‐1187. doi:10.1016/j.cell.2012.02.005 - DOI - PMC - PubMed
    1. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775‐789. doi:10.1038/nrd3179 - DOI - PMC - PubMed
    1. Ling H, Fabbri M, Calin GA. MicroRNAs and other non‐coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847‐865. doi:10.1038/nrd4140 - DOI - PMC - PubMed

Publication types